Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,475 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Renal Impairment Clear all

Conditions: End-stage Renal Disease, Malnutrition; Protein
Interventions: Intradialytic Parenteral Nutrition; Other
Lead sponsor: Patient Care America; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Pompano Beach, Florida

Conditions: Acute Renal Failure
Interventions: Selective cytopheretic device (SCD); Device
Lead sponsor: SeaStar Medical; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 7
States / cities: Birmingham, Alabama • San Diego, California • Denver, Colorado + 4 more

Conditions: Chronic Kidney Disease, Cardiovascular Disease
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Renal Insufficiency, Diabetes Mellitus
Interventions: Iodixanol 320-Arm 1, Iopamidol 300-Arm 2; Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Kidney Diseases
Interventions: Renasight; Diagnostic Test
Lead sponsor: Natera, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 31
States / cities: Anchorage, Alaska • Tucson, Arizona • Granada Hills, California + 23 more

Conditions: Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions: Home hospital care; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)
Interventions: Fabrazyme (agalsidase beta); Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 16 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 9
States / cities: Farmington, Connecticut • Coral Springs, Florida • Kansas City, Kansas + 6 more

Conditions: Infections, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulation, Diabetes and Its Complications, End of Life/Desires Only Medical Management
Interventions: Home Hospital care, Traditional Hospital care; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Quincy, Illinois • Hazard, Kentucky

Conditions: Peritoneal Dialysis Complication, Hypoalbuminemia, Malnutrition
Interventions: increased protein intake via natural foods, increase protein intake via protein supplements; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Riverside, California

Conditions: Renal Failure
Interventions: Enriched Hematopoietic Stem Cell Infusion; Biological
Lead sponsor: Talaris Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2024
U.S. locations: 2
States / cities: Chicago, Illinois • Louisville, Kentucky

Conditions: Acute Kidney Injury
Interventions: Conventional Foley Catheter(Medline), Accuryn Foley Catheter; Device
Lead sponsor: Dang Tan Phat; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Irvine, California

Conditions: Renal Insufficiency, Chronic, Kidney Disease, Chronic
Interventions: LY2928057, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 4
States / cities: Lakewood, Colorado • Orlando, Florida • Indianapolis, Indiana + 1 more

Conditions: End Stage Renal Disease
Interventions: Astagraf XL, Prograf, Mycophenolate mofetil; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 19 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Anesthesia, Surgery With General Anesthesia, Noncardiac Surgery, Hypotension During Surgery, Acute Kidney Injury (AKI), Myocardial Injury After Noncardiac Surgery (MINS), Vasopressor
Interventions: Norepinephrine, Phenylephrine; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 18,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: San Francisco, California • College Park, Maryland • Ann Arbor, Michigan + 6 more

Conditions: End Stage Renal Disease, Chronic Kidney Diseases
Interventions: Berinert, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: End Stage Renal Disease, Chronic Hepatitis c
Interventions: Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 34 Years to 44 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Renal Failure
Interventions: phlebotomy; Procedure
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Chronic Kidney Diseases
Interventions: Physical Activity Intervention; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Kidney Diseases, Renal Insufficiency
Interventions: ILY101; Drug
Lead sponsor: Ilypsa; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 18
States / cities: Mobile, Alabama • Mountain View, California • Riverside, California + 15 more

Conditions: Liver Cirrhosis
Interventions: Zibotentan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Renal Failure, Renal Artery Stenosis
Interventions: 62Cu-ethylglyoxal bis(thiosemicarbazone), 15O-water, Positron Emission Tomography; Drug · Procedure
Lead sponsor: Jeffrey L. Lacy; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Fluid Balance, Input and Output, Inflammatory Mediators, Acute Kidney Injury, Mortality
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Chronic Kidney Disease (CKD)
Interventions: Epoetin Hospira Arm, Standard of Care Arm, IV Iron; Biological · Other · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 42
States / cities: Chula Vista, California • Poway, California • Rancho Bernardo, California + 24 more

Conditions: Acute Renal Failure, Kidney Disease, Coronary Artery Disease
Interventions: IV isotonic saline, IV isotonic bicarbonate, N-acetylcysteine, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 5,177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 35
States / cities: Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 32 more

Search by objective public record fields.

Impact of IDPN on Nutrition Markers in Patients Receiving ICHD

Safety Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Renal Failure

Mechanisms of Chronic Kidney Disease (CKD)-Induced Foam Cell Formation

Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography

Renasight Clinical Application, Review and Evaluation (RenaCARE) Study

Rural Home Hospital: Proof of Concept

Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme

Rural Hospital-Level Care at Home for Acutely Ill Adults

The Effect of Natural Protein vs. Protein Supplements on Peritoneal Dialysis Patients

Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell Infusion

Intraabdominal Pressure Monitoring Urinary Catheter and Kidney Perfusion Pressure

A Study of LY2928057 in Hemodialysis Participants

Pharmacokinetics of Immunosuppressants in Renal Transplant Candidates Who Have Undergone Laparoscopic Sleeve Gastrectomy

The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery

Berinert (C1INH) vs Placebo for DGF/IRI

Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access

Immunosuppressive Effects of Mycophenolate Mofetil and Valganciclovir in Kidney Transplant Recipients

The Efficacy of Physical Activity on Improving Health Outcomes for Renal Transplant Patients

Efficacy and Tolerability of ILY101 in Dialysis Patients With Hyperphosphatemia

A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants

Renal Blood Flow Measurement With Positron Emission Tomography (PET)

Fluid Balance and Clinical Outcomes

A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis

Prevention of Serious Adverse Events Following Angiography